Global Blood Therapeutics, Inc. – NASDAQ:GBT

Add to watchlist

$68.49

Market closed

Open in about 7 hours

+1.02%

month

+108.81%

quarter

+162.21%

year

Market Cap	N/A
Enterprise value	4.88B

P/E	-14.08
EV/Sales	20.82
EV/EBITDA	-16.95
Price/Sales	19.12
Price/Book	37.95
PEG ratio	0.73
EPS	-5.07

Revenue	234.86M
EBITDA	-288.41M
Income	-326.37M
Revenue Q/Q	50.45%
Revenue Y/Y	42.52%

Profit margin	-137.3%
Oper. margin	-127.41%
Gross margin	98.1%
EBIT margin	-127.41%
EBITDA margin	-122.8%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Global Blood Therapeutics, Inc. (NASDAQ:GBT): Profit margin
Sep 2021	52.05M	-70.98M	-136.38%
Dec 2021	56.09M	-91.49M	-163.1%
Mar 2022	55.16M	-81.42M	-147.61%
Jun 2022	71.55M	-82.47M	-115.26%

Global Blood Therapeutics, Inc. (NASDAQ:GBT): Earnings per share (EPS)
2022-02-23	-1.13	-1.36
2022-05-04	-1.3	-1.26
2022-08-08	-1.18	-1.26

Global Blood Therapeutics, Inc. (NASDAQ:GBT): Debt to assets
Sep 2021	607678000	299.37M	49.27%
Dec 2021	939208000	742.79M	79.09%
Mar 2022	869543000	735.54M	84.59%
Jun 2022	870442000	752.08M	86.4%

Global Blood Therapeutics, Inc. (NASDAQ:GBT): Cash Flow
Sep 2021	-65.31M	-16.12M	45.09M
Dec 2021	-67.92M	-17.51M	387.17M
Mar 2022	-71.85M	-222.5M	1.60M
Jun 2022	-44.30M	-134.66M	48.59M

Global Blood Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Global Blood Therapeutics
Employees

Global Blood Therapeutics, Inc. (NASDAQ:GBT): Employee count
Aug 2023	457
Sep 2023	457
Oct 2023	457
Nov 2023	457
Dec 2023	457
Jan 2024	457
Feb 2024	457
Mar 2024	457
Apr 2024	457
May 2024	457
Jun 2024	457
Jul 2024	457

Global Blood Therapeutics
Hedge Funds Holdings Q1 2022

100.00% 0.00%

of GBT is owned by hedge funds

197 -3

hedge funds hold GBT stock

87.66M +22.32M

shares is hold by hedge funds

GBT hedge funds holdings changes

Global Blood Therapeutics
Insider Trading

Global Blood Therapeutics, Inc. (NASDAQ:GBT): Insider trades (number of shares)
Period	Buy	Sel
Jun 2022	0	3168
Aug 2022	0	4678
Sep 2022	0	31441

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	1 Oct 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Restricted Stock Units	182	N/A	N/A
Option	1 Oct 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Restricted Stock Units	1,375	N/A	N/A
Option	1 Oct 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Common Stock	182	N/A	N/A
Option	1 Oct 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Common Stock	1,375	N/A	N/A
Option	27 Sep 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Stock Option (Right to Buy)	83	$46.99	$3,900
Option	27 Sep 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Stock Option (Right to Buy)	1,027	$48.44	$49,748
Option	27 Sep 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Stock Option (Right to Buy)	2,043	$59.6	$121,763
Option	27 Sep 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Stock Option (Right to Buy)	3,005	$29.75	$89,399
Option	27 Sep 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Stock Option (Right to Buy)	23,597	$12.95	$305,581
Option	27 Sep 2022	HABIBIZAD NAZILA officer: Executive Vice President, Operat.. officer: Executive Vice Preside..	Common Stock	83	$46.99	$3,900

GBT insider trading transactions

Global Blood Therapeutics
Patents

Status	Patent	Filling date	Issue date
Application	Application PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS Filling date: 7 Feb 2022 Issue date: 25 Aug 2022	7 Feb 2022	25 Aug 2022
Application	Application PROCESS FOR PREPARATION OF 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALD- EHYDE Filling date: 5 Nov 2021 Issue date: 12 May 2022	5 Nov 2021	12 May 2022
Application	Application PROCESS FOR SYNTHESIZING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZAL- DEHYDE Filling date: 10 Jan 2022 Issue date: 5 May 2022	10 Jan 2022	5 May 2022
Application	Application COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN Filling date: 3 Jan 2022 Issue date: 21 Apr 2022	3 Jan 2022	21 Apr 2022
Application	Application DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALD- EHYDE Filling date: 22 Dec 2021 Issue date: 14 Apr 2022	22 Dec 2021	14 Apr 2022
Grant	Grant Utility: Ferroportin inhibitors and methods of use Filling date: 12 Dec 2019 Issue date: 29 Mar 2022	12 Dec 2019	29 Mar 2022
Grant	Grant Utility: Histone methyltransferase inhibitors Filling date: 15 Feb 2017 Issue date: 22 Feb 2022	15 Feb 2017	22 Feb 2022
Grant	Grant Utility: Compounds and uses thereof for the modulation of hemoglobin Filling date: 18 Mar 2019 Issue date: 1 Feb 2022	18 Mar 2019	1 Feb 2022
Application	Application AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS Filling date: 6 Aug 2021 Issue date: 2 Dec 2021	6 Aug 2021	2 Dec 2021
Application	Application SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION Filling date: 28 May 2021 Issue date: 23 Sep 2021	28 May 2021	23 Sep 2021

GBT patents

Global Blood Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2022 4 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 23 Feb 2022	Q4 2021 Earnings Call Transcript
Q3 2021 5 Nov 2021	Q3 2021 Earnings Call Transcript
Q2 2021 3 Aug 2021	Q2 2021 Earnings Call Transcript

GBT earnings call transcripts

Global Blood Therapeutics
Executives

Insider	Age	Compensation
Dr. Ted W. Love (1959) Pres, Chief Executive Officer & Director	66	$1,130,000
Mr. David L. Johnson (1969) Chief Commercial Officer	56	$702,750
Mr. Jeffrey S. Farrow (1962) Chief Financial Officer & Principal Accounting Officer	63	$694,310
Ms. Jung E. Choi (1970) Chief Bus. & Strategy Officer	55	$657,120
Ms. Patricia Borga Suvari (1961) Chief Legal Officer & Sec.	64	$641,500

Global Blood Therapeutics
Latest News

Friday, 16 September 2022
12:41	Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals	Seeking Alpha
Tuesday, 9 August 2022
14:43	Get ready for more merger mania in pharma sector the rest of the year	Market Watch
12:47	Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings	Zacks Investment Research
11:49	Pfizer is acquiring Global Blood Therapeutics	Invezz
06:18	Pfizer to buy Global Blood Therapeutics for US$5.4bn	Proactive Investors
Monday, 8 August 2022
14:51	Why Global Blood Therapeutics Stock Was Trouncing the Market Today	The Motley Fool
12:12	GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics	InvestorPlace
09:05	Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics	Investors Business Daily
09:01	Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.	Barrons
07:34	Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion	Pulse2
07:25	Pfizer reaches $5.4B deal for Global Blood Therapeutics	Fox Business
06:52	Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment	Market Watch
06:48	Pfizer to buy Global Blood Therapeutics in $5.4 billion deal	Reuters
06:37	Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ	Market Watch
Friday, 5 August 2022
13:35	Why Global Blood Therapeutics Stock Is Vaulting Higher Today	The Motley Fool
12:08	Pfizer in Talks to Buy Global Blood Therapeutics: Report	Barrons
11:58	WSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billion	Market Watch
11:44	Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ	Reuters
09:02	Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?	Zacks Investment Research
Thursday, 4 August 2022
14:42	Why Global Blood Therapeutics Stock Is Soaring Today	The Motley Fool
09:07	Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'	Market Watch
Tuesday, 26 July 2022
11:40	Earnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline	Zacks Investment Research
Thursday, 30 June 2022
14:52	Global Blood (GBT) Initiates Phase II Study on SCD Candidate	Zacks Investment Research
14:30	5 Top Biotech Stocks To Watch In July 2022	Stockmarketcom
Wednesday, 29 June 2022
15:27	Why Global Blood Therapeutics Trended Upward Today	The Motley Fool
Tuesday, 21 June 2022
18:31	Global Blood Therapeutics: Powerhouse Of The Future	Seeking Alpha
Thursday, 9 June 2022
09:58	7 No-Brainer Biotech Stocks to Add to Your Buy List	InvestorPlace
Tuesday, 7 June 2022
12:48	Global Blood's (GBT) Candidates for SCD Get Two FDA Tags	Zacks Investment Research
Wednesday, 1 June 2022
16:05	GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences	GlobeNewsWire
Thursday, 26 May 2022
12:48	Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 21 Sep 2022

Crispr: Elucidating And Forecasting Key Developments
Seeking Alpha 16 Sep 2022

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Seeking Alpha 15 Sep 2022

Regenxbio: A Transformative Year
Seeking Alpha 17 Aug 2022

Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed
Seeking Alpha 13 Aug 2022

Biopharmaceutical Stocks Continue To Perform Well, With Many Attractive Values Remaining
Seeking Alpha 21 Jun 2022

Global Blood Therapeutics: Powerhouse Of The Future
Seeking Alpha 12 Apr 2022

Global Blood Therapeutics: Hitting A Growth Inflection
Seeking Alpha 12 Mar 2022

Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Seeking Alpha 25 Dec 2021

Global Blood Therapeutics: Revisiting A Stellar Grower
Seeking Alpha 30 Nov 2021

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Frequently Asked Questions (FAQ)

What's the price of Global Blood Therapeutics stock today?

One share of Global Blood Therapeutics stock can currently be purchased for approximately $68.49.
When is Global Blood Therapeutics's next earnings date?

Unfortunately, Global Blood Therapeutics's (GBT) next earnings date is currently unknown.
Does Global Blood Therapeutics pay dividends?

No, Global Blood Therapeutics does not pay dividends.
What is Global Blood Therapeutics's stock symbol?

Global Blood Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GBT".
What is Global Blood Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Global Blood Therapeutics?

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Global Blood Therapeutics's key executives?
Global Blood Therapeutics's management team includes the following people:
- Dr. Ted W. Love Pres, Chief Executive Officer & Director(age: 66, pay: $1,130,000)
- Mr. David L. Johnson Chief Commercial Officer(age: 56, pay: $702,750)
- Mr. Jeffrey S. Farrow Chief Financial Officer & Principal Accounting Officer(age: 63, pay: $694,310)
- Ms. Jung E. Choi Chief Bus. & Strategy Officer(age: 55, pay: $657,120)
- Ms. Patricia Borga Suvari Chief Legal Officer & Sec.(age: 64, pay: $641,500)
How many employees does Global Blood Therapeutics have?

As Jul 2024, Global Blood Therapeutics employs 457 workers.
When Global Blood Therapeutics went public?

Global Blood Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 12 Aug 2015.
What is Global Blood Therapeutics's official website?

The official website for Global Blood Therapeutics is gbt.com.
Where are Global Blood Therapeutics's headquarters?

Global Blood Therapeutics is headquartered at 181 OYSTER POINT BLVD, South San Francisco, CALIFORNIA.
How can i contact Global Blood Therapeutics?

Global Blood Therapeutics's mailing address is 181 OYSTER POINT BLVD, South San Francisco, CALIFORNIA and company can be reached via phone at +1 650 741 7700.

Global Blood Therapeutics, Inc.

gbt.com

Exchange:

NASDAQ

Full time employees:

457

Industry:

Biotechnology

Sector:

Healthcare

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

+1 650 741 7700

181 OYSTER POINT BLVD
South San Francisco, CALIFORNIA 94080

CIK: 0001629137
ISIN: US37890U1088
CUSIP: 37890U108